Ovid Therapeutics Inc. (NASDAQ:OVID) shares are up during Wednesday’s session following the company’s announcement of new data regarding OV329 and the initiation of a Phase 1 trial for OV4071.

Epilepsy Data

Ovid Therapeutics reported favorable topline safety and tolerability findings from a 7 mg dose cohort of OV329 for drug-resistant epilepsies.

There were no treatment-related adverse events in the 7 mg cohort, and 19 unrelated adverse events, all of which were mild and transient.

Additionally, the company plans to expand OV329’s development to include tuberous sclerosis complex seizures and infantile spasms, with a proof-of-concept study for TSC expected to begin in the fourth quarter of 2026.

The company also received ...